home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences
Search  -  prev / next
 
 

Liquid Biopsy Assays: Beyond Recurrence Detection in Post-Diagnosis Cancer Management

 
  October 25, 2022  
     
 
Xtalks, online
2022 -12-02


MRD is rapidly emerging as a key biomarker in therapy development and patient care, however, key challenges remain. Personalis is committed to addressing some of the most pressing needs in the liquid biopsy space.
 
In this webinar attendees will learn about the role of next-generation liquid biopsy assays in enabling:
 

Earlier detection of disease recurrence
Utility in more disease indications, and at earlier stages of disease
Patient enrichment, screening/enrollment and surrogate endpoint analysis for clinical trials
Higher resolution variant tracking
Combining plasma and tissue analyses

 
 
Register to learn how liquid biopsy assays go beyond recurrence detection in post-diagnosis cancer management.
 
 
Organized by: Xtalks
Invited Speakers: Dan Norton, Associate Director, Product Management, Personalis Inc.
 
Deadline for Abstracts: 2022 -12-02
 
Registration: Free registration
E-mail: ajuurinen@xtalks.com
 
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2022 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.